[go: up one dir, main page]

HK1214764A1 - Method and composition for inducing autophagy - Google Patents

Method and composition for inducing autophagy Download PDF

Info

Publication number
HK1214764A1
HK1214764A1 HK16102727.8A HK16102727A HK1214764A1 HK 1214764 A1 HK1214764 A1 HK 1214764A1 HK 16102727 A HK16102727 A HK 16102727A HK 1214764 A1 HK1214764 A1 HK 1214764A1
Authority
HK
Hong Kong
Prior art keywords
autophagy
composition
subject
inducing autophagy
inducing
Prior art date
Application number
HK16102727.8A
Other languages
Chinese (zh)
Inventor
Rong-Tsun Wu
Lin-Yea HORNG
Hui-Ching SUNG
Li-Wen Chen
Original Assignee
吴淑芬
吴荣灿
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 吴淑芬, 吴荣灿 filed Critical 吴淑芬
Publication of HK1214764A1 publication Critical patent/HK1214764A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/07—Basidiomycota, e.g. Cryptococcus
    • A61K36/074—Ganoderma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Psychology (AREA)
  • Mycology (AREA)
  • Cardiology (AREA)
  • Biotechnology (AREA)
  • Anesthesiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Psychiatry (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

A method for inducing autophagy in a subject having an autophagy defect is provided. The method of the present invention includes the step of administering to the subject a therapeutically effective amount of a Ganoderma lucidum extract, wherein the autophagy enhances clearance of protein aggregates in the subject.
HK16102727.8A 2012-11-26 2012-11-26 Method and composition for inducing autophagy HK1214764A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2012/066547 2012-11-26
PCT/US2012/066547 WO2014081439A1 (en) 2012-11-26 2012-11-26 Method and composition for inducing autophagy

Publications (1)

Publication Number Publication Date
HK1214764A1 true HK1214764A1 (en) 2016-08-05

Family

ID=50776454

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16102727.8A HK1214764A1 (en) 2012-11-26 2012-11-26 Method and composition for inducing autophagy

Country Status (7)

Country Link
EP (1) EP2922556A4 (en)
JP (1) JP2016501861A (en)
CN (1) CN105050609A (en)
AU (1) AU2012394926A1 (en)
CA (1) CA2892157A1 (en)
HK (1) HK1214764A1 (en)
WO (1) WO2014081439A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016131945A1 (en) 2015-02-20 2016-08-25 Transgene Sa Combination product with autophagy modulator
CN105820204B (en) * 2016-03-16 2018-01-23 广西医科大学 Ganoderma lucidum olefin(e) acid and its production and use
CN106074566B (en) * 2016-06-02 2019-11-12 广西医科大学 Uses of Ganoderma Triterpenoids
TWI620566B (en) * 2016-11-04 2018-04-11 三華生物科技股份有限公司 Uses of a triterpenoid mixture for treating multiple sclerosis
CN107976545B (en) * 2017-12-05 2020-07-28 山西中医药大学 Method for screening cell autophagy regulator in vitro
CN109758486A (en) * 2019-03-25 2019-05-17 广州白云山汉方现代药业有限公司 Ganodenna Lucidum P.E is preparing the application in artitumor multi-medicine-resistant medicine
CN110330542B (en) * 2019-08-19 2021-09-14 遵义医学院附属医院 Compound for delaying human mesenchymal stem cell aging and preparation method and application thereof
CN113583958A (en) * 2021-08-02 2021-11-02 南通大学 Cell type identification method after induction of neural stem cell differentiation
CN114019078B (en) * 2022-01-04 2022-04-05 宝枫生物科技（北京）有限公司 Application of biomarker for Parkinson's disease diagnosis

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3502072B2 (en) * 2001-08-09 2004-03-02 ワンソーク ハン Health food composition for protecting liver (Healthy food composition for protecting hepatic)
EP2424552B1 (en) * 2009-04-29 2017-03-01 PuraPharm International (H.K.) Limited Ganoderma lucidum extracts for treating parkinson's disease

Also Published As

Publication number Publication date
AU2012394926A1 (en) 2015-05-28
CN105050609A (en) 2015-11-11
JP2016501861A (en) 2016-01-21
WO2014081439A1 (en) 2014-05-30
CA2892157A1 (en) 2014-05-30
EP2922556A1 (en) 2015-09-30
EP2922556A4 (en) 2016-07-06

Similar Documents

Publication Publication Date Title
HK1214764A1 (en) Method and composition for inducing autophagy
WO2014028777A3 (en) Methods of treating a tauopathy
MX357965B (en) Pharmaceutical composition for treatment and/or prevention of gall bladder cancer.
MX358224B (en) Pharmaceutical composition for treatment and/or prevention of liver cancer.
AR089993A1 (en) PEPTIDOMIMETIC MACROCICLES
WO2013081463A3 (en) Influenza a virus specific antibodies
WO2011113019A3 (en) Ctla4 proteins and their uses
MX2015007147A (en) A method of reducing brain amyloid plaques using anti-a㟠antibodies.
HK1214510A1 (en) Gla monotherapy for use in cancer treatment
HUE036542T2 (en) Peptides for use in the topical treatment of retinal neurodegenerative diseases, in particular in early stages of diabetic retinopathy and other retinal diseases in which neurodegeneration plays an essential role
WO2012017324A3 (en) Combination pharmaceutical composition and methods of treating diseases or conditions associated with neurodegenerative diseases
WO2012112315A3 (en) Methods for diagnosis of kawasaki disease
WO2013090635A3 (en) Composition and method for the diagnosis and treatment of iron-related disorders
WO2012017323A3 (en) Pharmaceutical composition and methods of treating and preventing the diseases caused by hiv or associated with hiv
MX2016008397A (en) Composition for use in the treatment of persistent cough.
WO2015001013A3 (en) Human anti-ifn-alpha antibodies
WO2014033158A3 (en) Pcsk9 peptide vaccine
WO2016007919A3 (en) Antibody fragments for detecting cancer and methods of use
EP3034515A4 (en) Fusion protein of ganoderma lucidum immunoregulatory protein and human serum albumin, and production method therefor and uses thereof
EP3080246A4 (en) Compositions and methods for producing and administering brown adipocytes
WO2014064609A3 (en) HERBAL COMPOSITION FOR THE PREVENTION AND TREATMENT OF TNF-α MEDIATED DISEASES
EP3362793A4 (en) Method for detecting neutralizing antibodies against recombinant human insulin in human serum
EP3288542A4 (en) Compositions and methods for administering antibodies
WO2011088020A9 (en) Modified saponins for the treatment of fungal infections
WO2014169011A3 (en) Methods for treating immune diseases